Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2022 09:01 ET | Source: Genmab A/S

Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)

Media Release Copenhagen, Denmark, November 3, 2022 Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody®-CD3xCD20) in a...
October 28, 2022 08:45 ET | Source: Genmab A/S

Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release COPENHAGEN, Denmark; October 28, 2022 Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamabEuropean Medicines Agency...
October 18, 2022 06:35 ET | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022

Company Announcement Net sales of DARZALEX® in the third quarter of 2022 totaled USD 2,052 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN,...
October 05, 2022 15:56 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 5, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
September 27, 2022 12:43 ET | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; September 27, 2022 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 18,406 shares as a consequence of the exercise of employee warrants. The...
September 20, 2022 15:20 ET | Source: Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; September 20, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 19,782 restricted stock units and 19,789 warrants to employees...
September 06, 2022 10:53 ET | Source: Genmab A/S

Genmab to Present at Morgan Stanley 20th Annual Global Healthcare Conference

Media ReleaseCOPENHAGEN, Denmark; September 6, 2022 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will...
September 01, 2022 12:27 ET | Source: Genmab A/S

Completion of share buy-back program

Company Announcement COPENHAGEN, Denmark; September 1, 2022 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on August 31, 2022. On June 17, 2022 Genmab...
August 29, 2022 05:04 ET | Source: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; August 29, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
August 24, 2022 14:52 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; August 24, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...